Search results for "E-F"

showing 10 items of 836 documents

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

2010

On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on da…

AdultMalemedicine.medical_specialtyNeutropeniaFCR RegimenKaplan-Meier EstimateOfatumumabSeverity of Illness IndexGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Monoclonal Murine-Derivedchemistry.chemical_compoundChemoimmunotherapyObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansImmunologic FactorsMedicineCyclophosphamideAgedAged 80 and overbusiness.industryIncidenceAntibodies MonoclonalLeukopeniaGeneral MedicineMiddle AgedLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineTreatment OutcomechemistryDisease ProgressionFemaleRituximabRefractory Chronic Lymphocytic LeukemiaRituximabbusinessVidarabineUntreated Chronic Lymphocytic Leukemiamedicine.drug
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Torque decrease during submaximal evoked contractions of the quadriceps muscle is linked not only to muscle fatigue.

2015

International audience; The aim of this study was to analyze the neuromuscular mechanisms involved in the torque decrease induced by submaximal electromyostimulation (EMS) of the quadriceps muscle. It was hypothesized that torque decrease after EMS would reflect the fatigability of the activated motor units (MUs), but also a reduction in the number of MUs recruited as a result of changes in axonal excitability threshold. Two experiments were performed on 20 men to analyze 1) the supramaximal twitch superimposed and evoked at rest during EMS (Experiment 1, n = 9) and 2) the twitch response and torque-frequency relation of the MUs activated by EMS (Experiment 2, n = 11). Torque loss was asses…

AdultMalemedicine.medical_specialtyPhysiology[ SDV.MHEP.AHA ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]recruitment ordermotor unit activationhuman skeletal-muscleperipheral fatigueIsometric exercisenerveisometric contractionQuadriceps MusclePhysiology (medical)Internal medicinemedicineTorqueHumansvoluntaryelectrical stimulationMotor NeuronsMuscle fatiguebusiness.industryElectromyographyQuadriceps muscletorque-frequency relationfemorisAnatomyneuromuscular electrical-stimulationtwitch interpolationElectric StimulationTorquefrequency[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Muscle FatigueCardiologyfemoral nerve stimulationbusinessFemoral NerveMuscle ContractionJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

A clinical-pathological and survival study of oral squamous cell carcinomas from a population of the North of Portugal

2014

Objectives: Our aim was to analyze the clinical, pathological, and outcome characteristics of oral squamous cell carcinomas (OSCC) from a population of the north of Portugal. Material and Methods: We conducted a descriptive study of 128 OSCC diagnosed between the years of 2000 and 2010 in the Centro Hospitalar do Porto. Through of the review of the clinical records we studied several clinical, pathological, and outcome variables. The overall survival (OS) and disease-free survival (DFS) were analyzed by Kaplan-Meier method and log-rank test. Cox regression method was used for multivariate analysis. Results: Of 128 patients with OSCC, 83 (64.8%) were male and 45 (35.2%) were female, (mean ag…

AdultMalemedicine.medical_specialtyPopulationOdontologíaGastroenterologyDisease-Free SurvivalYoung AdultInternal medicineSquamous cell carcinomaOral and maxillofacial pathologymedicineHumansYoung adulteducationGeneral DentistrySurvival ratePathologicalAgedRetrospective StudiesAged 80 and overMouth neoplasmeducation.field_of_studyOral Medicine and PathologyPortugalProportional hazards modelbusiness.industryResearchmouth neoplasmsRetrospective cohort studyMiddle Agedoral cancerPrognosis:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgerySurvival Ratestomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellFemaleMouth NeoplasmsSurgeryprognosisbusinessoral pathology
researchProduct

A Comparison of Five Maintenance Therapies for Reflux Esophagitis

1995

Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued.We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patients were initially treated with omeprazole (40 mg orally once a day) for four to eight weeks, and healing was confirmed by endoscopy. Participants were then stratified according to their initial grade of esophagitis and randomly assigned to 12 months of treatment with one of the following: cisapride (10 mg three times a day), ranitidine (150 mg three times a day), omeprazole (20 mg per day), ranitidine plus cisapride (10 mg three times a day), or …

AdultMalemedicine.medical_specialtyRanitidineSeverity of Illness IndexGastroenterologyDisease-Free SurvivalRanitidinePiperidinesRecurrenceInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesReflux esophagitisProspective cohort studyEsophagitis PepticOmeprazoleCisapridemedicine.diagnostic_testEsophageal diseasebusiness.industryGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseaseSurgeryEndoscopyTreatment OutcomeHistamine H2 AntagonistsCisaprideDrug Therapy CombinationFemaleEsophagoscopybusinessEsophagitisOmeprazolemedicine.drugNew England Journal of Medicine
researchProduct

A unique fatal case of Waterhouse–Friderichsen syndrome caused by Proteus mirabilis in an immunocompetent subject

2019

Abstract Introduction: The Waterhouse–Friderichsen syndrome (WFS), also known as purpura fulminans, is a potentially lethal condition described as acute hemorrhagic necrosis of the adrenal glands. It is often caused by infection. Classically, Neisseriae meningitidis represents the main microorganism related to WFS, although, infrequently, also other infectious agents are reported as a possible etiologic agent. The authors report the first case of death due to Proteus mirabilis infection, with postmortem evidence of WFS. Patient concerns: After a facial trauma that provoked a wound on the nose, the subject, a healthy 40-years old man, was conducted to the local hospital (in Sicily, Italy) af…

AdultMalemedicine.medical_specialtySepsiforensic sciencesAutopsyGastroenterologysepsisSepsisImmunocompromised Host03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicineWaterhouse–Friderichsen syndromeHumansClinical Case Report030212 general & internal medicineLeukocytosisProteus mirabilisWaterhouse-Friderichsen syndromeDisseminated intravascular coagulationbiology4900business.industryBilateral massive adrenal hemorrhageWaterhouse-Friderichsen syndrome: XGeneral Medicinemedicine.diseasebiology.organism_classificationProteus InfectionProteus mirabilisBilateral massive adrenal hemorrhage; Forensic sciences; Proteus mirabilis infection; Sepsis; Waterhouse-Friderichsen syndrome; Adult; Humans; Male; Proteus Infections; Waterhouse-Friderichsen Syndrome; Immunocompromised Host; Proteus mirabilisProteus mirabilis infection030220 oncology & carcinogenesisForensic sciencemedicine.symptomProteus InfectionsbusinessAdrenal HemorrhageResearch ArticleHumanPurpura fulminansMedicine
researchProduct

Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

2019

We analyzed the outcomes of 26 consecutive patients with acquired severe aplastic anemia (SAA) undergoing peripheral blood stem cell transplantation (PBSCT) with partial ex vivo T cell depletion with a targeted T cell dose from HLA-identical sibling donors. The median patient age was 37 years (range, 3 to 63 years). Four patients with uncontrolled pneumonia at the time of transplantation died, on days +1, +2, +21, and +26. All evaluable patients engrafted, with a median time to neutrophil recovery of 11 days (range, 10 to 14 days) and a median time to platelet recovery of 19 days (range, 8 to 53 days). Two patients had transient grade I acute graft-versus-host disease (GVHD) with skin invol…

AdultMalemedicine.medical_specialtySevere aplastic anemiaAdolescentT-LymphocytesT cellGraft vs Host DiseaseHuman leukocyte antigenSeverity of Illness IndexGastroenterologyDisease-Free SurvivalLymphocyte DepletionHLA AntigensInternal medicinemedicineHumansCumulative incidenceSiblingChildAllogeneic stem cell transplantation Ex vivo T cell depletion Matched sibling donor Severe aplastic anemiaEx vivo T cell depletionMatched sibling donorPeripheral Blood Stem Cell TransplantationTransplantationbusiness.industryHistocompatibility TestingSiblingsAnemia AplasticHematologyMiddle AgedAllograftsmedicine.diseaseSevere Aplastic AnemiaTissue DonorsAllogeneic stem cell transplantationSurvival RateTransplantationPneumoniasurgical procedures operativemedicine.anatomical_structureChild PreschoolAcute DiseasebusinessEx vivoFollow-Up StudiesBiology of Blood and Marrow Transplantation
researchProduct

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

2015

The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial.Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m(2) on days 1, 8, and 15 every 4 weeks or dacarbazine 1000 mg/m(2) every 3 weeks. The primary end point was progression-free survival (PFS) by independent radiologic review; the secondary end point was overall survival (OS).A total of 529 patients were randomized to nab-paclitaxel (n = 264) or dacarbazine (n = 265). Baseline characteristics were well balanced. The majority of patients were men (66%), had an Eastern Cooperative Oncology Group status of 0 (7…

AdultMalemedicine.medical_specialtySkin NeoplasmsPaclitaxelDacarbazineGastroenterologyDisease-Free Survivallaw.inventionYoung AdultRandomized controlled triallawInternal medicineAlbuminsmedicineClinical endpointHumansProgression-free survivalAntineoplastic Agents AlkylatingMelanomaAgedAged 80 and overbusiness.industryMelanomaHazard ratioHematologyOriginal ArticlesMiddle Agedmedicine.diseaseChemotherapy regimenConfidence intervalSurgeryDacarbazineOncologyFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late ch…

2007

The introduction of Imatinib (IM) has significantly altered the treatment for CML, although only limited follow-up results are available. As failure of Interferon-alpha had been associated with poor prognosis and results of IM-treatment in this patient group may allow earlier estimation of long-term benefits for early chronic phase patients. Therefore we prospectively analyzed the quality and duration of remissions and the rate of BCR-ABL resistance mutations occurring in patients treated with IM, if they were intolerant or refractory to interferon. Fifty-nine patients were included and median follow up is 4.75 years. Haematologic remission rate was 92% and 62% of patients achieved at least…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classAntineoplastic AgentsBiologyGastroenterologyTyrosine-kinase inhibitorDisease-Free SurvivalPiperazinesMedian follow-upInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase InhibitorsSurvival analysisAgedRetrospective StudiesHematologyImatinibHematologyMiddle Agedmedicine.diseaseSurvival AnalysisLeukemiaImatinib mesylatePyrimidinesImmunologyBenzamidesImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugAmerican journal of hematology
researchProduct

Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial

2018

Abstract Background It is not clear whether all patients with rectal cancer need chemoradiotherapy. A restrictive use of neoadjuvant chemoradiotherapy (nCRT) based on MRI findings for rectal cancer was investigated in this study. Methods This prospective multicentre observational study included patients with stage cT2–4 rectal cancer, with any cN and cM0 status. Carcinomas in the middle and lower third that were 1 mm or less from the mesorectal fascia, all cT4 tumours, and all cT3 tumours of the lower third were classified as high risk, and these patients received nCRT followed by total mesorectal excision (TME). All other carcinomas with a minimum distance of more than 1 mm from the mesore…

AdultMalemedicine.medical_specialtyTime FactorsColorectal cancermedicine.medical_treatment030230 surgeryDisease-Free Survival03 medical and health sciences0302 clinical medicineCarcinomamedicineHumansProspective StudiesStage (cooking)Prospective cohort studyNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overRectal Neoplasmsbusiness.industryIncidenceIncidence (epidemiology)ChemoradiotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTotal mesorectal excisionNeoadjuvant TherapyEuropeSurvival RateTreatment Outcome030220 oncology & carcinogenesisFemaleSurgeryRadiologyNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up StudiesBritish Journal of Surgery
researchProduct